NeoSync, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NeoSync, Inc. - overview
Established
2008
Location
South Boston, MA, US
Primary Industry
Healthcare IT
About
Founded in 2008, NeoSync, Inc. is based in Boston, US, NeoSync is a clinical-stage company dedicated to advancing treatments for major depressive disorder and other central nervous system conditions. In September 2025, Grow Therapy, a portfolio company of TCV, Goldman Sachs Asset Management, Plus Capital, Transformation Capital, SignalFire, and SVB, acquired NeoSync, Inc. from Valiance.
The firm offers a proprietary platform called NEST®, which delivers personalized, low-energy brain stimulation in a non-invasive manner. The technology synchronizes stimulation with individual EEG patterns, aiming to improve therapeutic outcomes while maintaining safety and comfort. NeoSync emphasizes research-driven innovation, with completed, ongoing, and planned clinical trials supporting its approach. Its mission is to pioneer personalized neuromodulation therapies that offer alternatives to traditional treatments, setting a new standard in the field of mental health and neurological care.
Current Investors
Grow Therapy
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT, Mental Health Services, Analytics & Performance Software, Medical Software
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.